{"id":198073,"date":"2024-10-19T12:36:36","date_gmt":"2024-10-19T12:36:36","guid":{"rendered":"https:\/\/pdfstandards.shop\/product\/uncategorized\/aami-tir17137-2014\/"},"modified":"2024-10-25T05:09:50","modified_gmt":"2024-10-25T05:09:50","slug":"aami-tir17137-2014","status":"publish","type":"product","link":"https:\/\/pdfstandards.shop\/product\/publishers\/aami\/aami-tir17137-2014\/","title":{"rendered":"AAMI TIR17137 2014"},"content":{"rendered":"
Outlines design verification and validation considerations for absorbable cardiovascular implants. Applies to implants in direct contact with the cardiovascular system, where the intended action is upon the circulatory system.<\/p>\n
PDF Pages<\/th>\n | PDF Title<\/th>\n<\/tr>\n | ||||||
---|---|---|---|---|---|---|---|
1<\/td>\n | ANSI\/AAMI\/ISO TIR17137:2014, Cardiovascular implants and extracorporeal systems \u2013 Cardiovascular absorbable <\/td>\n<\/tr>\n | ||||||
3<\/td>\n | Title page <\/td>\n<\/tr>\n | ||||||
4<\/td>\n | Copyright information <\/td>\n<\/tr>\n | ||||||
5<\/td>\n | AAMI Technical Information Report ANSI Technical Report <\/td>\n<\/tr>\n | ||||||
6<\/td>\n | Contents <\/td>\n<\/tr>\n | ||||||
7<\/td>\n | Glossary of equivalent standards <\/td>\n<\/tr>\n | ||||||
8<\/td>\n | Committee representation <\/td>\n<\/tr>\n | ||||||
9<\/td>\n | Background on ANSI\/AAMI adoption of ISO\/TS 17137:2014 <\/td>\n<\/tr>\n | ||||||
10<\/td>\n | Foreword <\/td>\n<\/tr>\n | ||||||
11<\/td>\n | Introduction <\/td>\n<\/tr>\n | ||||||
13<\/td>\n | 1 Scope 2 Normative references <\/td>\n<\/tr>\n | ||||||
14<\/td>\n | 3 Terms and definitions <\/td>\n<\/tr>\n | ||||||
15<\/td>\n | 4 Implant considerations 4.1 Classification 4.2 Intended clinical performance 4.3 Intended clinical use <\/td>\n<\/tr>\n | ||||||
16<\/td>\n | 4.4 Materials 4.5 Packaging, labelling, and sterilization 4.5.1 Packaging 4.5.1.1 General 4.5.1.2 Considerations for absorbable product 4.5.2 Labelling 4.5.2.1 Label(s) <\/td>\n<\/tr>\n | ||||||
17<\/td>\n | 4.5.2.2 Instructions for use (IFU) <\/td>\n<\/tr>\n | ||||||
18<\/td>\n | 4.5.3 Sterilization 4.5.3.1 General 4.5.3.2 Radiation sterilization 4.5.3.3 Ethylene oxide sterilization 4.5.3.4 Steam sterilization 4.5.3.5 Alternative sterilization <\/td>\n<\/tr>\n | ||||||
19<\/td>\n | 4.6 Risk management 4.6.1 General 4.6.2 Failure modes 4.6.3 Risk mitigation 4.6.4 Specific aspects for absorbable implants <\/td>\n<\/tr>\n | ||||||
20<\/td>\n | Figure 1 \u2014 Life cycle of one single device\/implant 5 Design verification and validation \u2014 Testing and analysis 5.1 Overview <\/td>\n<\/tr>\n | ||||||
21<\/td>\n | Figure 2 \u2014 Schematic representation of stages in the degradation of an absorbable implant 5.2 Considerations in the characterization and assessment of material and implant properties 5.2.1 General considerations <\/td>\n<\/tr>\n | ||||||
23<\/td>\n | 5.2.2 Drug-substrate Interaction considerations 5.2.3 Summary of in vitro evaluation steps <\/td>\n<\/tr>\n | ||||||
24<\/td>\n | 5.3 in vitro procedural assessment 5.3.1 Conditioning of test samples 5.3.2 Assessment of delivery and placement <\/td>\n<\/tr>\n | ||||||
25<\/td>\n | 5.3.3 Assessment of initial function post-deployment 5.4 in vitro degradation assessment (post procedure) 5.4.1 General <\/td>\n<\/tr>\n | ||||||
26<\/td>\n | 5.4.2 Implant integrity 5.4.2.1 Mechanical evaluation 5.4.2.2 Cyclic fatigue durability 5.4.2.3 Physical characterization of degradation\/corrosion <\/td>\n<\/tr>\n | ||||||
27<\/td>\n | 5.4.2.4 Material composition assessment 5.4.2.5 Other property assessments 5.4.2.5.1 Corrosion\/degradation 5.4.2.5.2 Evaluate clinically using relevant imaging modalities <\/td>\n<\/tr>\n | ||||||
28<\/td>\n | 5.4.2.5.3 Radiopacity 5.4.2.5.4 MRI compatibility 5.5 in vitro-in vivo correlation (IVIVC) 5.6 Biocompatibility 5.6.1 General considerations <\/td>\n<\/tr>\n | ||||||
29<\/td>\n | 5.6.2 Sterilization considerations 5.6.3 Drug-device combination product considerations 5.7 Pre-clinical in vivo evaluation 5.7.1 Purpose <\/td>\n<\/tr>\n | ||||||
30<\/td>\n | 5.7.2 Specific aims 5.7.3 Protocol <\/td>\n<\/tr>\n | ||||||
32<\/td>\n | 5.7.4 Data acquisition 5.7.5 Test report and additional information 5.8 Clinical considerations specific to absorbable implants 5.8.1 Purpose 5.8.2 Specific aims 5.8.3 Clinical-investigation plan <\/td>\n<\/tr>\n | ||||||
33<\/td>\n | 5.8.4 Data acquisition 5.8.5 Final report 5.8.6 Post market surveillance 5.9 Shelf life considerations 5.9.1 General information <\/td>\n<\/tr>\n | ||||||
34<\/td>\n | 5.9.2 Real time aging 5.9.3 Accelerated aging <\/td>\n<\/tr>\n | ||||||
35<\/td>\n | Annex A: Nomenclature of absorb, degrade and related terms <\/td>\n<\/tr>\n | ||||||
36<\/td>\n | Bibliography <\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":" AAMI\/ISO TIR17137:2014 – Cardiovascular implants and extracorporeal systems-Cardiovascular absorbable implants<\/b><\/p>\n |